Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s product pipeline includes batoclimab and IMVT-1402, both of which are fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor. Co. is developing batoclimab, its first prodcut candidate, and IMVT-1402, its second product candidate, in autoimmune diseases for which there is evidence that pathogenic IgG antibodies drive disease manifestation. Co. is developing batoclimab for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves' disease. The IMVT average annual return since 2019 is shown above.
The Average Annual Return on the IMVT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMVT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMVT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free IMVT Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
